Evidence map›Paper›PMID 40672318›Full record

ArticlebioRxiv : the preprint server for biology2025

Selective disruption of lipid peroxide homeostasis in intratumoral regulatory T cells by targeting FSP1 enhances cancer immunity.

Jesse Garcia Castillo, Stephanie Silveria, Antoine Sauquet, Leo Schirokauer, Joseph Hendricks, Hei Sook Sul, James A Olzmann, Michel DuPage

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Jesse Garcia CastilloDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0001-5786-7914
Stephanie SilveriaDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.
Antoine SauquetDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.
Leo SchirokauerDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.
Joseph HendricksDivision of Molecular Therapeutics, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.
Hei Sook SulDepartment of Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, CA 94720, USA.
James A OlzmannDivision of Molecular Therapeutics, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0001-7751-8316
Michel DuPageDivision of Immunology and Molecular Medicine, Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.ORCID 0000-0002-1479-9840

Funding

Molecular Mechanisms of Lipid Droplet BiogenesisR01GM112948 · NIGMS · UNIVERSITY OF CALIFORNIA BERKELEY · PI OLZMANN, JAMES A · 2015 to 2024
$3.1M
Engineering precision cancer immunotherapyDP2CA247830 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI DUPAGE, MICHEL · 2019 to 2019
$2.4M
NCI NIH HHS DP2 CA247830NIGMS NIH HHS R01 GM112948
6 · The paper itself

Abstract

A burgeoning approach to treat cancer is the pharmacological induction of ferroptotic cell death of tumor cells. However, the impact of disrupting anti-ferroptotic pathways in the broader tumor microenvironment (TME), such as in immune cells, is still undefined and may complicate treatments. Here, we show that Ferroptosis Suppressor Protein 1 (FSP1

Identifiers

PMID40672318
PMCPMC12265646

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.